Scopolamine Market is Anticipated to Witness High Growth Owing to Rising Incidences of Motion Sickness

Scopolamine Market is Anticipated to Witness High Growth Owing to Rising Incidences of Motion Sickness

 It acts as a competitive antagonist at muscarinic acetylcholine receptors in the central and peripheral nervous system. Scopolamine is primarily used to treat or prevent motion sickness and postoperative nausea and vomiting. It is available in various formulations such as tablets, patches, injections and creams. Scopolamine patches and tablets are commonly used for preventing motion sickness during travel by sea, air or land. The scopolamine market is growing due to the rising incidences of motion sickness worldwide and increasing awareness about its treatment options.

The Global Scopolamine Market is estimated to be valued at US$ 4235.74 Mn in 2024 and is expected to exhibit a CAGR of 3.8% over the forecast period from 2024 to 2030.

Key Takeaways

Key players operating in the scopolamine market are Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therapeutix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, Marine Polymer Technologies, Inc. Key opportunities in the scopolamine market include the rising number of surgical procedures worldwide and increasing adoption of tissue-engineered products for hernia repair, skin/soft tissue repair and breast reconstruction. Geographically, North America dominates the global scopolamine market driven by growing investments in research and development activities. However, Asia Pacific is expected to witness highest growth during the forecast period due to rising medical tourism and increasing healthcare spending in China and India.

Market Drivers
Increase in the number of surgeries performed - Continuous innovation in surgical techniques and equipments has increased the number of complex surgeries being performed. As scopolamine provides effective post-operative pain management and anti-nausea effects, the demand from surgical procedures is anticipated to propel market growth during the forecast period.

Market Restrains
Side effects associated with excessive dosage - Scopolamine Market Size  has strong anticholinergic effects which may cause side effects like dry mouth, blurred vision, constipation, difficulty in urination etc. at high doses. Risk of side effects limits its widespread adoption and acts as a major market restraint.

Segment Analysis
The scopolamine market is segmented based on route of administration, application and end-user. By route of administration, the transdermal segment holds the largest market share as it is a non-invasive mode of delivery and allows for continuous drug release over an extended period of time. The intravenous segment is expected to grow the fastest during the forecast period owing to growing preference for intravenous route over oral administration in clinical settings for rapid onset of action.

By application, the motion sickness segment dominates the market due to high and growing prevalence of disorders like seasickness and motion sickness. The surgeries segment is poised to increase at a high rate during the analysis period on account of growing volume of surgeries globally and need for intraoperative administration of scopolamine.

Based on end-user, hospitals hold the highest share in the scopolamine market as they are the primary treatment providers for diseased conditions requiring scopolamine therapy. The ambulatory surgery centers end-user segment is projected to expand rapidly over the next few years as they offer outpatient surgical procedures at lower costs than hospitals.

Global Analysis

Regionally, North America commands the leading position in the global scopolamine market driven by advanced healthcare infrastructure, rising incidence of post-operative nausea and vomiting, and growing surgical procedures in the region. Asia Pacific market is estimated to witness lucrative growth during the forecast period attributed to surging healthcare spending, developing pharmaceutical industry and increasing demand for premium healthcare products in emerging countries like India and China.
​
For more Insights, Read –
https://www.newswirestats.com/scopolamine-market-market-size-and-share-analysis/